摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7-dimethoxy-4-methylsulfonyl-1,2,3-benzotriazine | 99161-54-3

中文名称
——
中文别名
——
英文名称
6,7-dimethoxy-4-methylsulfonyl-1,2,3-benzotriazine
英文别名
4-Methanesulfonyl-6,7-dimethoxy-1,2,3-benzotriazine
6,7-dimethoxy-4-methylsulfonyl-1,2,3-benzotriazine化学式
CAS
99161-54-3
化学式
C10H11N3O4S
mdl
——
分子量
269.281
InChiKey
KGOSZHDEFDLCKK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    99.6
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • Benzotriazines having adenosine uptake inhibitor activity
    申请人:Kyowa Hakko Kogyo Co., Ltd.
    公开号:US05605900A1
    公开(公告)日:1997-02-25
    The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C-R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen), or a pharmaceutically acceptable salt thereof as an active ingredient.
    本发明涉及一种腺苷摄取抑制剂和用于心肌保护或预防或治疗炎性水肿的药剂,包括由式(I)表示的1,2,3,4-四氢-2,4-二氧喹唑啉衍生物:其中R.sup.1表示氢,取代或未取代的较低烷基,烯基或取代或未取代的芳基烷基;R.sup.2,R.sup.3,R.sup.4和R.sup.5独立地表示氢,卤素,氨基,单或二(较低烷基)氨基,较低烷酰胺基,硝基,氰基,取代或未取代的较低烷基,羟基,较低烷氧基,较低烷基硫基,羧基,较低烷氧羰基,较低烷酰基,芳基烷氧基或较低烷氧基酰氧基;R.sup.6,R.sup.7,R.sup.8和R.sup.9独立地表示氢,羟基,取代或未取代的较低烷氧基或芳基烷氧基,或其中任意相邻的两个被结合形成亚甲二氧基;R.sup.10表示氢或较低烷基;Y和Z独立地表示N或C-R.sup.11(其中R.sup.11表示氢,取代或未取代的较低烷基或卤素),或其药学上可接受的盐作为活性成分。
  • Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
    申请人:Kyowa Hakko Kogyo Co., Ltd.
    公开号:US05624926A1
    公开(公告)日:1997-04-29
    The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen), or a pharmaceutically acceptable salt thereof as an active ingredient.
    本发明涉及一种腺苷摄取抑制剂和用于心肌保护、预防或治疗炎性水肿的药剂,包括由式(I)表示的1,2,3,4-四氢-2,4-二氧喹唑啉衍生物:##STR1## 其中R.sup.1表示氢、取代或未取代的低级烷基、烯基或取代或未取代的芳基烷基;R.sup.2、R.sup.3、R.sup.4和R.sup.5独立地表示氢、卤素、氨基、单-或双(低级烷基)氨基、低级烷酰胺基、硝基、氰基、取代或未取代的低级烷基、羟基、低级烷氧基、低级烷硫基、羧基、低级烷氧羰基、低级烷酰基、芳基烷氧基或低级烷氧羰氧基;R.sup.6、R.sup.7、R.sup.8和R.sup.9独立地表示氢、羟基、取代或未取代的低级烷氧基或芳基烷氧基,或其中任意相邻的两个结合形成亚甲二氧基;R.sup.10表示氢或低级烷基;Y和Z独立地表示N或C-R.sup.11(其中R.sup.11表示氢、取代或未取代的低级烷基或卤素),或其药学上可接受的盐作为活性成分。
  • Isoquinolines having adenosine uptake inhibitor activity
    申请人:Kyowa Hakko Kogyo Co., Ltd.
    公开号:US05658917A1
    公开(公告)日:1997-08-19
    The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen), or a pharmaceutically acceptable salt thereof as an active ingredient.
    本发明涉及一种腺苷摄取抑制剂和用于心肌保护或预防或治疗炎性水肿的药剂,包括由式(I)表示的1,2,3,4-四氢-2,4-二氧喹唑啉衍生物:##STR1## 其中R.sup.1表示氢,取代或未取代的低碳基,烯基或取代或未取代的芳基甲基;R.sup.2、R.sup.3、R.sup.4和R.sup.5分别表示氢,卤素,氨基,单-或二(低碳基)氨基,低烷酰胺基,硝基,氰基,取代或未取代的低碳基,羟基,低烷氧基,低烷硫基,羧基,低烷氧羰基,低烷酰基,芳基甲氧基或低烷氧基酰氧基;R.sup.6、R.sup.7、R.sup.8和R.sup.9独立地表示氢,羟基,取代或未取代的低烷氧基或芳基甲氧基,或其中任意相邻两个结合形成亚甲二氧基;R.sup.10表示氢或低碳基;Y和Z独立地表示N或C--R.sup.11(其中R.sup.11表示氢,取代或未取代的低碳基或卤素),或其药学上可接受的盐作为活性成分。
  • ADENOSINE INCORPORATION INHIBITOR
    申请人:KYOWA HAKKO KOGYO KABUSHIKI KAISHA
    公开号:EP0638567A1
    公开(公告)日:1995-02-15
    An adenosine incorporation inhibitor and a drug for protecting cardiac muscles or preventing or treating inflammatory edema, each containing as the active ingredient a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, wherein R¹ represents hydrogen, (un)substituted lower alkyl, alkenyl or (un)substituted aralkyl; R², R³, R⁴ and R⁵ represent each independently hydrogen, halogen, amino, mono- or di(lower alkyl) amino, lower alkanoyl amino, nitro, cyano, (un)substituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy or lower alkanoyloxy; R⁶, R⁷, R⁸ and R⁹ represent each independently hydrogen, hydroxy, (un)substituted lower alkoxy or aralkyloxy, or alternatively the two adjacent groups among them may be combined together to represent methylenedioxy; R¹⁰ represents hydrogen or lower alkyl; and Y and Z represent each independently N or C-R'', wherein R'' represents hydrogen, (un)substituted lower alkyl or halogen.
    一种腺苷掺入抑制剂和一种保护心肌或预防或治疗炎症性水肿的药物,各自含有通式(I)代表的 1,2,3,4-四氢-2,4-二氧代喹唑啉衍生物或其药理学上可接受的盐作为活性成分,其中 R¹ 代表氢、(未)取代的低级烷基、烯基或(未)取代的芳烷基;R²、R³、R⁴ 和 R⁵ 各自独立地代表氢、卤素、氨基、单或二(低级烷基)氨基、低级烷酰基氨基、硝基、氰基、(未)取代的低级烷基、羟基、低级烷氧基、低级烷硫基、羧基、低级烷氧基羰基、低级烷酰基、芳氧基或低级烷酰氧基;R⁶、R⁷、R⁸ 和 R𠞙 各自独立地代表氢、羟基、(未)取代的低级烷氧基或芳氧基,或者其中相邻的两个基团可结合在一起代表亚甲基二氧基;R¹⁰ 代表氢或低级烷基;以及 Y 和 Z 各自独立地代表 N 或 C-R'',其中 R'' 代表氢、(未)取代的低级烷基或卤素。
  • NOMOTO, YUJI;OBASE, HIROYUKI;TAKAI, HARUKI;TERANISHI, MASAYUKI;NAKAMURA, +, CHEM. AND PHARM. BULL., 38,(1990) N, C. 2179-2183
    作者:NOMOTO, YUJI、OBASE, HIROYUKI、TAKAI, HARUKI、TERANISHI, MASAYUKI、NAKAMURA, +
    DOI:——
    日期:——
查看更多

同类化合物

苯并咪唑并[1,2-C][1,2,3]苯并三嗪 硫代磷酸 O,O-二甲基 S-((4-氧代-1,2,3-苯并三嗪-3(4H)-基)甲基)酯 益棉磷 吗林那宗 保棉磷 N,N,N',N'-四甲基-O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)脲四氟硼酸盐(TDBTU) 8-甲氧基苯并[D][1,2,3]三嗪-4(3H)-酮 7-甲硫基-8,9,10-三氮杂双环[4.4.0]癸-1,3,5,7,9-五烯 7-乙氧基-6-甲氧基-4-(4-三氟甲基苯胺基)-1,2,3-苯并三嗪 7-乙氧基-6-甲氧基-4-(3-三氟甲基苯胺基)-1,2,3-苯并三嗪 7-乙氧基-4-(4-氟-3-三氟甲基苯胺基)-6-甲氧基-1,2,3-苯并三嗪 7-乙氧基-4-(3-氟-4-溴苯胺基)-6-甲氧基-1,2,3-苯并三嗪 7-乙氧基-4-(2-氟苯胺基)-6-甲氧基-1,2,3-苯并三嗪 6-硝基-1,2,3-苯并三嗪-4(1H)-酮2-氧化物 6-甲氧基-4-(4-氟苯胺基)-7-戊氧基-1,2,3-苯并三嗪 6-氟苯并[D][1,2,3]三嗪-4(1H)-酮 6-氟-3-羟基-1,2,3-苯并三嗪-4-酮 5-氯苯并[D][1,2,3]三嗪-4(3H)-酮 5-氟苯并[D][1,2,3]三嗪-4(3H)-酮 4-(4-甲氧基苯基)-1,2,3-苯并三嗪 4-(4-溴-3-氟苯胺基)-6-甲氧基-7-戊氧基-1,2,3-苯并三嗪 4-(3-氯-4-氟苯基氨基)-苯并[d] [1,2,3]三嗪 4-(3,5-二氟苯胺基)-6-甲氧基-7-戊氧基-1,2,3-苯并三嗪 3-苯基-1,2,3-苯并三嗪-4(3H)-酮 3-羟基甲基-4-酮苯并-1,2,3-噻嗪 3-羟基-8-(三氟甲基)苯并[D][1,2,3]三嗪-4(3H)-酮 3-羟基-7-甲基-1,2,3-苯并三嗪-4-酮 3-羟基-6-甲基苯并[D][1,2,3]三嗪-4(3H)-酮 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 3-甲基苯并三嗪-4-酮 3-环己基-1,2,3-苯并三嗪-4-酮 3-氯甲基-3-苯并噻嗪-4(3H)-酮 3-哌啶-4-基-3H-苯并[d] [1,2,3]三嗪-4-酮 3-吡啶-2-基-1,2,3-苯并三嗪-4-酮 3-丙-2-烯基-1,2,3-苯并三嗪-4-酮 3-丁氧基-1,2,3-苯并三嗪-4-酮 3-[(甲氧基-甲硫基磷酰)巯基甲基]-1,2,3-苯并三嗪-4-酮 3-(氯甲氧基)-1,2,3-苯并三嗪-4-酮 3-(哌啶-4-基)苯并[D][1,2,3]三嗪-4(3H)-酮盐酸盐 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 3-(二乙氧基磷酰硫基甲基)-1,2,3-苯并三嗪-4-酮 3-(4-溴苯基)-1,2,3-苯并三嗪-4(3H)-酮 3-(4-氧代-1,2,3-苯并三嗪-3(4H)-基)丙酸 3-(2-苯基乙烯基)-1,2,3-苯并三嗪-4-酮 3-(2-甲基吡唑-3-基)-1,2,3-苯并三嗪-4-酮 3-(2-溴苯基)-1,2,3-苯并三嗪-4-酮 3-(1-乙氧基乙基)-1,2,3-苯并三嗪-4-酮 3,4-二氢-4-亚氨基-3-丙基-1,2,3-苯并三嗪 2-(内-5-降冰片烯-2,3-二羧酰亚胺)-1,1,3,3-四甲基脲六氟磷酸盐 2-(4-氧代-4H-苯并[d] [1,2,3]三嗪-3-基)-苯甲酸